摘要:
Only a single, standard-independent clock rate is generated in a signal processor or a signal processing structure, and correspondingly only precisely one clock frequency generator is then arranged on the chip. The signal processing path includes at least one controllable, asynchronous decimator for transposing the reception signals present in a uniform time frame into a respective standard-specific time frame. This enables signals of a variety of mobile phone standards to be processed.
摘要:
The proposed iterative method concurrently calculates maximum likelihood estimated values for the channel coefficients (h0, . . . , hL; θh) and the DC offset (d; θd) on the basis of a training sequence (TSC) in a TDMA mobile communications system. The SAGE algorithm leads to two recursion formulae, by means of which the iterative calculation of estimated values for the channel coefficients (h0, . . . , hL; θh) and for the DC offset (d; θd) is provided.
摘要翻译:所提出的迭代方法同时计算信道系数的最大似然估计值(h 0 0,...,h L 2,θH 2)和 基于TDMA移动通信系统中的训练序列(TSC)的DC偏移(dθθd)。 SAGE算法导致两个递归公式,通过该公式,对于信道系数(h 0,...,h L 2,..., SUB> h SUB>)和DC偏移(d;θ SUB>)。
摘要:
Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R1 is aryl; R2 is a bicyclic heteroaryl group comprising one ring nitrogen atom with the exception that R2 cannot represent 2-phthalimidyl; any of R3, R4, R5 and R6, independently of the other, is H or a substituent other than hydrogen; and R7 and R8, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.
摘要:
A device for scaling and quantization of digital soft output values (sk) from an equalizer has a control loop for controlling a statistical parameter (θ) for the scaled and quantized soft output values (sD,k), which contains a calculation unit (4) for calculation of the statistical parameter (θ), and a control unit (5) for calculation of a scaling factor (c) for scaling the soft output values (sk) from the equalizer on the basis of the statistical parameter (θ).
摘要:
In order to compensate for a frequency offset or a change in the phase of the transmission channel over time during mobile radio transmission of data symbols, the data symbols are transmitted by way of carrier-frequency, modulated data bursts. Sample values of the received signal, which are known in advance and correspond to first and second symbols, are evaluated in order to estimate the frequency offset or the change in the phase of the transmission channel over time. These first and second symbols are transmitted with a defined phase angle by way of the data burst, and are arranged separated from one another in the data burst. Edge symbols in a data burst are advantageously used as first and second symbols, or as a symbol pair, for estimation.
摘要:
In a method for correlative estimation of a mobile radio channel on the basis of a training sequence (TS) which is transmitted via the mobile radio channel, a sequence of P received symbols is correlated with a subsequence of length P of the training sequence, in order to calculate a first estimated channel coefficient (ĥ0(1)). Furthermore, the same sequence of P received symbols is correlated with at least some of the subsequences of the training sequence (TS) shifted through ±1, ±2, . . . , ±(Lt−1) symbol positions, in order to calculate a number of further estimated channel coefficients (ĥ±1(1),ĥ±2(1), . . . ,ĥ±(Lt−1)(1)).
摘要:
In a method to compensate for a step DC disturbance (1) in a baseband signal in a homodyne radio receiver, the time profile of the step DC disturbance within a burst is determined. In order to produce a step-corrected baseband signal, the determined time profile (2) is then calculated from the digitized baseband signal.
摘要:
Described are compounds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is S02; R1 is aryl; R2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R2 cannot represent 2-phthalimidyl, and in case of Y=SO2 cannot represent 2,1,3-benzothiadiazol-4-yl; any of R3, R4, R5 and R6, independently of the other, is H or a substituent other than hydrogen; and R7 and R8, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.
摘要翻译:描述了式(I)的化合物,其中W是O或S; X为NR8; Y为CR 9 R 10 - (CH 2)n,其中R 9和R 10彼此独立地为氢或低级烷基,n为0〜3的整数。 或Y为SO2; R1是芳基; R2是包含一个或多个环氮原子的单环或双环杂芳基,除了R 2不能表示2-邻苯二酰亚氨基,并且在Y = SO 2的情况下不能代表2,1,3-苯并噻二唑-4-基; R 3,R 4,R 5和R 6中的任何一个独立地为H或氢以外的取代基; 且R 7和R 8彼此独立地为H或低级烷基; 或N-氧化物或其药学上可接受的盐在制备用于治疗对VEGF受体酪氨酸激酶活性的抑制作出反应的肿瘤疾病的药物产品中的用途。 式(I)化合物可用于治疗,例如, 的肿瘤疾病,如肿瘤疾病,视网膜病变和年龄相关性黄斑变性。
摘要:
This invention relates to pyrimidine derivatives of general formula I in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.
摘要:
This invention relates to pyrimidine derivatives of general formula I in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.